Prestige Brands Holdings, Inc.—ranked No. 39 in Happi’s 2014 Top 50 Report—has agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle Federal Trade Commission charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige owns Dramamime, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs. Dramiamine and Insight’s Bonine, are the only...